FDA approves decitabine and cedazuridine oral tablets for Myelodysplastic Syndromes

Approval was based on a trial which showed similar blood concentrations vs intravenous decitabine. Decitabine/cedazuridine is intended to be taken once a day for 5 days of each cycle. Cedazuridine is a DNA cytidine deaminase inhibitor which enables oral delivery of decitabine.


Biospace Inc.